Turmeric Efficacy for Mobility and Joint Function (T-MOTION)
Primary Purpose
Knee Discomfort, Joint Pain
Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Turmipure GOLD®
Turmeric rhizome PE 95% curcuminoids
Placebo
Sponsored by
About this trial
This is an interventional prevention trial for Knee Discomfort focused on measuring Mobility, Joint function, Turmeric, Curcuminoids
Eligibility Criteria
Inclusion Criteria:
- Consent to the study and to comply with study product
- Who have a BMI between 18 and 32 kg/m²
- Who has mild to moderate knee pain for at least 3 months before enrollment (VAS between 40 to 70 on 100mm scale after respecting a washout period depending on the half-life of the excluded medications)
- Who has radiographic evidence of Kellgren-Lawrence score 0, 1, 2 and 3 in the tibio-femoral compartment of the target knee
- Who is able to perform the physical performance-based tests and understands all questions from the WOMAC questionnaire
- Who is willing to refrain from taking any pain reliever (OTC or prescription) and other pharmacological, nutritional agent (e.g. glucosamine), device or therapy (e.g. acupuncture) which may influence the study outcome during the entire trial (other than determined authorized rescue medication)
- Who is willing to not change dietary habits, level of physical activity (including any heavy physical work with high loading of the knee joints) and body weight
Exclusion Criteria:
- Subjects with any clinically significant levels of the safety parameters at screening
- Pregnant or lactating females, or wishing to become pregnant during the study
- Subject with joint pain related to some predisposing conditions that have adversely altered the joint tissues often due to a specific cause
- Subject with Kellgren-Lawrence grade 4 in the tibio-femoral compartment of the target knee
- Who has clinically apparent tense effusion of the target knee or other joint
- Who has/had viscosupplementation in any joint including the target knee or other joint within 6 months prior to screening
- Who has concomitant inflammatory disease or other condition that affects the joints deemed exclusionary by the Principal Investigator (e.g. rheumatoid arthritis, metabolic bone disease, psoriasis, gout, symptomatic chondrocalcinosis and active infection, etc…)
- Who has symptomatic osteoarthritis of the contralateral knee that is not responsive to paracetamol and requires other therapy
- Who is taking any treatment/supplementation which may interfere with study conduct and interpretation of study results (4-weeks washout, e.g. glucosamine, chondroitin, corticosteroids) except calcium and vitamin D supplements
- Who is under any medical condition deemed exclusionary by the Principal Investigator
- Subject has a history of drug and / or alcohol abuse at the time of enrollment
- Change of dietary habit within the preceding month
- Subject with known organic disease, including an inflammatory bowel disease, a benign or malign tumor of intestine or colon and significant systemic disease
- Subject currently involved in any other clinical trial or having participated in a trial within the preceding 90 days
- Subject with known allergy to components of the test product
- Subject has any concurrent medical or psychiatric condition that, in the opinion of the Investigator, would compromise his/her ability to comply with the study requirements
- History of cancer within the last 5 years, except basal cell carcinoma, non-squamous skin carcinoma, prostate cancer or carcinoma in situ with no significant progression over the past 2 years
- Significant cardiovascular, pulmonary, renal, liver, infectious disease, immune disorder, or metabolic/endocrine disorders or other disease that would preclude supplement ingestion and/or assessment of safety and the study objectives
- Current illnesses which could interfere with the study (e.g. prolonged severe diarrhea, regurgitation/severe, difficulty swallowing)
- Who is taking any anticoagulant or heparin treatment
Sites / Locations
- Poliklinika Aviva
- Poliklinika Idassa
- Ortopedska bolnišnica Valdoltra
- Splošna bolnišnica Jesenice, Oddelek za ortopedijo
- Bisturmed, d.o.o., Ortopedija in fizioterapija
- Poliklinika Nobilis, d.o.o., enota LJ, Ortopedska ambulanta
- Medicinsko termalni center Fontana, d.o.o., Ortopedska ambulanta
- Univerzitetni klinični center Maribor, Oddelek za ortopedijo
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Active Comparator
Placebo Comparator
Arm Label
TPG
STE
Control
Arm Description
59 participants who meet the eligibility criteria will be randomized under experimental arm and will receive Turmipure GOLD® product during 12 weeks
59 participants who meet the eligibility criteria will be randomized under experimental arm and will receive standard turmeric extract 95% curcuminoids (STE) product during 12 weeks
59 participants who meet the eligibility criteria will be randomized under experimental arm and will receive placebo (maltodextrin) product during 12 weeks
Outcomes
Primary Outcome Measures
Change in WOMAC™ Pain
Knee joint pain discomfort assessed with the validated Western Ontario and McMaster University questionnaire (WOMAC) using its visual analogue scale version (VAS). The WOMAC VA 3.1 Pain subscore (WOMAC A) ranges from 0 to 100 mm (averaging five VAS 0-100 mm) with higher scores indicating more pain.
Secondary Outcome Measures
Change in WOMAC™ Stiffness
Knee joint stiffness assessed with the validated Western Ontario and McMaster University questionnaire (WOMAC) using its visual analogue scale version (VAS). The WOMAC VA 3.1 Stiffness subscore (WOMAC B) ranges from 0 to 100 mm (averaging two VAS 0-100 mm) with higher scores indicating more stiffness.
Change in WOMAC™ Physical function
Knee joint physical function assessed with the validated Western Ontario and McMaster University questionnaire (WOMAC) using its visual analogue scale version (VAS). The WOMAC VA 3.1 Physical function subscore (WOMAC C) ranges from 0 to 100 mm (averaging seventeen VAS 0-100 mm) with higher scores indicating more stiffness.
Change in WOMAC™ Global Index
Knee joint global discomfort assessed through the sum of WOMAC A (pain), WOMAC B (stiffness) and WOMAC C (physical function) subscores. The WOMAC Global Index score ranges from 0 to 2400 mm (summing up twenty-four VAS 0-100 mm), with higher scores indicating higher disease burden.
Pain intensity at rest
The pain intensity at rest is assessed using a VAS ranging from 0 to 100 mm, with higher scores indicating more pain.
Pain intensity while walking
The pain intensity while walking is assessed using a VAS ranging from 0 to 100 mm, with higher scores indicating more pain.
"Patient Global Assessment" (PGA)
The "Patient Global Assessment" (PGA) is the global assessment on joint discomfort and is assessed using a VAS ranging from 0 to 100 mm, with higher scores indicating more pain.
OMERACT-OARSI criteria
Evaluation of the response to supplementation
30s Chair Stand Physical Performance
Evaluation of the maximum number of chair stand repetitions possible in a 30 second period. Scoring results in a wide range of skill levels from 0, for those who cannot complete a single repetition and values greater than 20 for the well prepared individuals.
40m Fast-paced Walked Physical Performance
A fast-paced walking test that is timed over 4 x 10m (33 ft) for a total 40 m (132 ft) evaluating the ability to walk quickly over short distances. Time of one test trial is recorded and expressed as speed m/s by dividing distance (40m) by time (s).
Stair Climb Physical Performance
Evaluates the time (in seconds) it takes to ascend and descend a flight of stairs. Timing begins on the signal to start and terminates when the participant returns with both feet to the ground level and the total time to ascend and descend steps for 1 test trial is recorded to nearest 100th of a second.
Time up & Go Physical Performance
Evaluates the time (seconds) taken to rise from a chair, walk 3 m (9 ft 10 inches), turn, walk back to the chair, then sit down. Timing starts on the signal to start and terminates once the participant sits back down fully with their back resting on the back of the chair. Two trials are performed and the faster of the 2 trials is recorded to nearest 10th of a second.
Quality of Life evaluation
Evaluation of Quality of life through SF-36 (RAND version), which is a set of generic, coherent, and easily administered quality-of-life measures. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability and the higher the score the less disability.
Clinical Global Impression of Change (CGIC)
Physician assessment of joint swelling and range of motion (ROM) for knee extension/flexion, indicating the perceived change over the treatment period. The clinician is requested to choose one of seven categories. Scores range from very much improved to very much worse.
Assessment of use of rescue medicine
Evaluation of associated treatments needed to manage joint complains
Full Information
NCT ID
NCT04506411
First Posted
July 29, 2020
Last Updated
May 2, 2023
Sponsor
Naturex SA
Collaborators
Artialis, Vizera d.o.o.
1. Study Identification
Unique Protocol Identification Number
NCT04506411
Brief Title
Turmeric Efficacy for Mobility and Joint Function
Acronym
T-MOTION
Official Title
Placebo Controlled Randomized Clinical Trial to Evaluate Efficacy of Turmipure Gold® to Improve Joint Function in Subjects With Distinct Kellgren-Lawrence Knee Radiographic Scores
Study Type
Interventional
2. Study Status
Record Verification Date
May 2023
Overall Recruitment Status
Completed
Study Start Date
September 24, 2020 (Actual)
Primary Completion Date
March 3, 2023 (Actual)
Study Completion Date
March 3, 2023 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Naturex SA
Collaborators
Artialis, Vizera d.o.o.
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The objective of the study is to test the capacity of a 12-weeks Turmipure GOLD® supplementation to reduce joint discomfort.
Detailed Description
The aim of this clinical study is to determine whether oral administration of Turmipure GOLD® can contribute to the improvement of mobility and joint function in adult population with knee discomfort and with distinct Kellgren-Lawrence (K&L) knee radiographic scores.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Knee Discomfort, Joint Pain
Keywords
Mobility, Joint function, Turmeric, Curcuminoids
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
177 (Actual)
8. Arms, Groups, and Interventions
Arm Title
TPG
Arm Type
Experimental
Arm Description
59 participants who meet the eligibility criteria will be randomized under experimental arm and will receive Turmipure GOLD® product during 12 weeks
Arm Title
STE
Arm Type
Active Comparator
Arm Description
59 participants who meet the eligibility criteria will be randomized under experimental arm and will receive standard turmeric extract 95% curcuminoids (STE) product during 12 weeks
Arm Title
Control
Arm Type
Placebo Comparator
Arm Description
59 participants who meet the eligibility criteria will be randomized under experimental arm and will receive placebo (maltodextrin) product during 12 weeks
Intervention Type
Dietary Supplement
Intervention Name(s)
Turmipure GOLD®
Intervention Description
TPG: Turmipure GOLD® capsules - 4 capsules once daily- as prescribed
Intervention Type
Dietary Supplement
Intervention Name(s)
Turmeric rhizome PE 95% curcuminoids
Intervention Description
STE: Turmeric rhizome PE 95% curcuminoids - 4 capsules once daily- as prescribed
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo
Intervention Description
Placebo: Maltodextrin - 4 capsules once daily- as prescribed
Primary Outcome Measure Information:
Title
Change in WOMAC™ Pain
Description
Knee joint pain discomfort assessed with the validated Western Ontario and McMaster University questionnaire (WOMAC) using its visual analogue scale version (VAS). The WOMAC VA 3.1 Pain subscore (WOMAC A) ranges from 0 to 100 mm (averaging five VAS 0-100 mm) with higher scores indicating more pain.
Time Frame
12-weeks
Secondary Outcome Measure Information:
Title
Change in WOMAC™ Stiffness
Description
Knee joint stiffness assessed with the validated Western Ontario and McMaster University questionnaire (WOMAC) using its visual analogue scale version (VAS). The WOMAC VA 3.1 Stiffness subscore (WOMAC B) ranges from 0 to 100 mm (averaging two VAS 0-100 mm) with higher scores indicating more stiffness.
Time Frame
12-weeks
Title
Change in WOMAC™ Physical function
Description
Knee joint physical function assessed with the validated Western Ontario and McMaster University questionnaire (WOMAC) using its visual analogue scale version (VAS). The WOMAC VA 3.1 Physical function subscore (WOMAC C) ranges from 0 to 100 mm (averaging seventeen VAS 0-100 mm) with higher scores indicating more stiffness.
Time Frame
12-weeks
Title
Change in WOMAC™ Global Index
Description
Knee joint global discomfort assessed through the sum of WOMAC A (pain), WOMAC B (stiffness) and WOMAC C (physical function) subscores. The WOMAC Global Index score ranges from 0 to 2400 mm (summing up twenty-four VAS 0-100 mm), with higher scores indicating higher disease burden.
Time Frame
12-weeks
Title
Pain intensity at rest
Description
The pain intensity at rest is assessed using a VAS ranging from 0 to 100 mm, with higher scores indicating more pain.
Time Frame
12-weeks
Title
Pain intensity while walking
Description
The pain intensity while walking is assessed using a VAS ranging from 0 to 100 mm, with higher scores indicating more pain.
Time Frame
12-weeks
Title
"Patient Global Assessment" (PGA)
Description
The "Patient Global Assessment" (PGA) is the global assessment on joint discomfort and is assessed using a VAS ranging from 0 to 100 mm, with higher scores indicating more pain.
Time Frame
12-weeks
Title
OMERACT-OARSI criteria
Description
Evaluation of the response to supplementation
Time Frame
12-weeks
Title
30s Chair Stand Physical Performance
Description
Evaluation of the maximum number of chair stand repetitions possible in a 30 second period. Scoring results in a wide range of skill levels from 0, for those who cannot complete a single repetition and values greater than 20 for the well prepared individuals.
Time Frame
12-weeks
Title
40m Fast-paced Walked Physical Performance
Description
A fast-paced walking test that is timed over 4 x 10m (33 ft) for a total 40 m (132 ft) evaluating the ability to walk quickly over short distances. Time of one test trial is recorded and expressed as speed m/s by dividing distance (40m) by time (s).
Time Frame
12-weeks
Title
Stair Climb Physical Performance
Description
Evaluates the time (in seconds) it takes to ascend and descend a flight of stairs. Timing begins on the signal to start and terminates when the participant returns with both feet to the ground level and the total time to ascend and descend steps for 1 test trial is recorded to nearest 100th of a second.
Time Frame
12-weeks
Title
Time up & Go Physical Performance
Description
Evaluates the time (seconds) taken to rise from a chair, walk 3 m (9 ft 10 inches), turn, walk back to the chair, then sit down. Timing starts on the signal to start and terminates once the participant sits back down fully with their back resting on the back of the chair. Two trials are performed and the faster of the 2 trials is recorded to nearest 10th of a second.
Time Frame
12-weeks
Title
Quality of Life evaluation
Description
Evaluation of Quality of life through SF-36 (RAND version), which is a set of generic, coherent, and easily administered quality-of-life measures. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability and the higher the score the less disability.
Time Frame
12-weeks
Title
Clinical Global Impression of Change (CGIC)
Description
Physician assessment of joint swelling and range of motion (ROM) for knee extension/flexion, indicating the perceived change over the treatment period. The clinician is requested to choose one of seven categories. Scores range from very much improved to very much worse.
Time Frame
12-weeks
Title
Assessment of use of rescue medicine
Description
Evaluation of associated treatments needed to manage joint complains
Time Frame
12-weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
35 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Consent to the study and to comply with study product
Who have a BMI between 18 and 32 kg/m²
Who has mild to moderate knee pain for at least 3 months before enrollment (VAS between 40 to 70 on 100mm scale after respecting a washout period depending on the half-life of the excluded medications)
Who has radiographic evidence of Kellgren-Lawrence score 0, 1, 2 and 3 in the tibio-femoral compartment of the target knee
Who is able to perform the physical performance-based tests and understands all questions from the WOMAC questionnaire
Who is willing to refrain from taking any pain reliever (OTC or prescription) and other pharmacological, nutritional agent (e.g. glucosamine), device or therapy (e.g. acupuncture) which may influence the study outcome during the entire trial (other than determined authorized rescue medication)
Who is willing to not change dietary habits, level of physical activity (including any heavy physical work with high loading of the knee joints) and body weight
Exclusion Criteria:
Subjects with any clinically significant levels of the safety parameters at screening
Pregnant or lactating females, or wishing to become pregnant during the study
Subject with joint pain related to some predisposing conditions that have adversely altered the joint tissues often due to a specific cause
Subject with Kellgren-Lawrence grade 4 in the tibio-femoral compartment of the target knee
Who has clinically apparent tense effusion of the target knee or other joint
Who has/had viscosupplementation in any joint including the target knee or other joint within 6 months prior to screening
Who has concomitant inflammatory disease or other condition that affects the joints deemed exclusionary by the Principal Investigator (e.g. rheumatoid arthritis, metabolic bone disease, psoriasis, gout, symptomatic chondrocalcinosis and active infection, etc…)
Who has symptomatic osteoarthritis of the contralateral knee that is not responsive to paracetamol and requires other therapy
Who is taking any treatment/supplementation which may interfere with study conduct and interpretation of study results (4-weeks washout, e.g. glucosamine, chondroitin, corticosteroids) except calcium and vitamin D supplements
Who is under any medical condition deemed exclusionary by the Principal Investigator
Subject has a history of drug and / or alcohol abuse at the time of enrollment
Change of dietary habit within the preceding month
Subject with known organic disease, including an inflammatory bowel disease, a benign or malign tumor of intestine or colon and significant systemic disease
Subject currently involved in any other clinical trial or having participated in a trial within the preceding 90 days
Subject with known allergy to components of the test product
Subject has any concurrent medical or psychiatric condition that, in the opinion of the Investigator, would compromise his/her ability to comply with the study requirements
History of cancer within the last 5 years, except basal cell carcinoma, non-squamous skin carcinoma, prostate cancer or carcinoma in situ with no significant progression over the past 2 years
Significant cardiovascular, pulmonary, renal, liver, infectious disease, immune disorder, or metabolic/endocrine disorders or other disease that would preclude supplement ingestion and/or assessment of safety and the study objectives
Current illnesses which could interfere with the study (e.g. prolonged severe diarrhea, regurgitation/severe, difficulty swallowing)
Who is taking any anticoagulant or heparin treatment
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Matija Tomšič, Prof., MD
Organizational Affiliation
Univerzitetni klinični center Ljubljana, Klinični oddelek za revmatologijo, Ljubljana, Slovenia
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Samo K Fokter, MD
Organizational Affiliation
Univerzitetni klinični center Maribor, Oddelek za ortopedijo
Official's Role
Principal Investigator
Facility Information:
Facility Name
Poliklinika Aviva
City
Zagreb
Country
Croatia
Facility Name
Poliklinika Idassa
City
Zagreb
Country
Croatia
Facility Name
Ortopedska bolnišnica Valdoltra
City
Ankaran
Country
Slovenia
Facility Name
Splošna bolnišnica Jesenice, Oddelek za ortopedijo
City
Jesenice
Country
Slovenia
Facility Name
Bisturmed, d.o.o., Ortopedija in fizioterapija
City
Koper
Country
Slovenia
Facility Name
Poliklinika Nobilis, d.o.o., enota LJ, Ortopedska ambulanta
City
Ljubljana
Country
Slovenia
Facility Name
Medicinsko termalni center Fontana, d.o.o., Ortopedska ambulanta
City
Maribor
Country
Slovenia
Facility Name
Univerzitetni klinični center Maribor, Oddelek za ortopedijo
City
Maribor
Country
Slovenia
12. IPD Sharing Statement
Plan to Share IPD
Undecided
IPD Sharing Plan Description
To revisit after investigation period
Learn more about this trial
Turmeric Efficacy for Mobility and Joint Function
We'll reach out to this number within 24 hrs